Lung Cancer

Tecemotide (INN; emepepimut-S (USAN); formerly known as BLP25 or EMD 531444) is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine (formerly known as Stimuvax, L-BLP25, BLP25 liposomal vaccine, or BLP25 liposome vaccine).

Read more in the app

Chinese Medical Journal article sheds light on the global lifetime risk of lung cancer - EurekAlert

Fibroblastic reticula cells can organize T cells in the fight against lung cancer

Signs of Lung Cancer Can Now Be Detected When You Exhale

AI analysis of PET/CT images can predict side effects of immunotherapy in lung cancer - EurekAlert

Scientists use microcellular drones to deliver lung cancer-killing drugs - EurekAlert

Scientists use microcellular drones to deliver lung cancer-killing drugs

Detecting evidence of lung cancer in exhaled breath

Detecting evidence of lung cancer in exhaled breath - EurekAlert

New Subtype of Lung Cancer Discovered in Young, Non-Smoking Patients

Lung Cancer: Researchers Find Three Subtypes of Tumors in People That Never Smoked

Study links methylmalonic acid to weakening of immune cells in lung cancer

Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer

Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer - EurekAlert

Study: Drug improves effectiveness of radiation for lung cancer that has spread to the brain - EurekAlert

Drug improves effectiveness of radiation for lung cancer that has spread to the brain

Chinese Medical Journal investigates recent and future trends of lung cancer - EurekAlert

Combination treatment improves response to immunotherapy for lung cancer

PM2.5 exposure may affect lung cancer in women who have never smoked - EurekAlert

Artificial intelligence method could advance gene mutation prediction in lung cancer

Researchers use AI tools to uncover connections between radiotherapy for lung cancer and heart complications